Maze Therapeutics, Inc. (MAZE) AI Stock Analysis

• Market Cap: $659.52M
• Dividend Yield: N/A
• Average Volume (3M): 263.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 43,850,883
• 10 Day Avg. Volume: 455,243
• 30 Day Avg. Volume: 263,289
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 119.41
• Enterprise Value/Gross Profit: 646.14
• Enterprise Value/Ebitda: -2.40
• 1Y Price Target: $27.20
• Price Target Upside: 71.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 59 Neutral
• Price Target: ―

Maze Therapeutics shows strong financial performance with significant revenue and cash flow improvements, yet the negative equity presents a substantial risk. Technical indicators suggest potential weakness in stock momentum, and lack of valuation metrics prevents a comprehensive assessment. Overall, the stock's strengths in financial growth are tempered by balance sheet risks and technical analysis concerns.

Positive Factors

Financial Performance

Maze remains eligible to receive up to $605 million in additional milestones and up to twenty percent tiered royalties on net sales from a partnership.

Market Potential

The expected clinical data for MZE782 could inform large market opportunities in phenylketonuria and chronic kidney disease.

Product Innovation

MZE829’s dual mechanism of action likely sets it apart from the current AMKD treatment landscape, potentially delaying disease progression and reversing patients out of disease.

Negative Factors

Clinical Trial Risk

A miss in the MZE782 readout risks cutting CKD probability of success.

Competitive Threat

A potential Jnana approval for JNT-517 in PKU could trim 5–10% off the stock unless Maze can differentiate on efficacy or tolerability.

Market Cap Limitations

Vertex's potential interim might set the bar for a class effect in AMKD, which could cap Maze's upside.

Maze Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

How the Company Makes Money

Maze Therapeutics generates revenue through a combination of strategic partnerships, collaborations, and the development and commercialization of its own therapeutic products. The company partners with other biotech and pharmaceutical companies to co-develop therapies, often receiving milestone payments and royalties from these collaborations. Additionally, Maze invests in its proprietary drug development programs, aiming to bring its therapies to market and generate revenue from product sales. The company's revenue model is heavily reliant on research and development success, regulatory approvals, and the establishment of lucrative partnerships that provide funding and market access for its innovations.

Maze Therapeutics, Inc. Financial Statement Overview

Summary

Maze Therapeutics exhibits robust revenue and cash flow growth, marking a significant turnaround from prior years. However, the balance sheet remains weak with negative equity, indicating potential financial risk. Despite profitability and operational efficiency, high leverage and negative equity could pose challenges to long-term stability.

Income Statement

Maze Therapeutics experienced significant improvement with revenue reaching $167.5M in 2024, up from zero in previous years, representing a strong revenue growth. Gross Profit Margin is 100% due to revenue equaling gross profit, indicating excellent cost management. Net Profit Margin is 31.2%, reflecting profitability. EBIT and EBITDA margins are healthy at 34.4% and 36.3%, respectively, demonstrating efficient operations.

Balance Sheet

The company has a negative stockholders' equity of -$311.18M, indicating financial instability. Debt-to-Equity ratio is not calculable due to negative equity. The equity ratio is negative, reflecting high leverage and potential financial risk. However, the company has substantial cash reserves, with cash holdings exceeding total debt.

Cash Flow

Maze Therapeutics shows strong cash flow performance with a substantial improvement in operating cash flow to $75.95M in 2024, up from a negative position. Free Cash Flow is positive at $74.81M, indicating effective cash management. Operating Cash Flow to Net Income ratio is 1.45, suggesting efficient conversion of income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	2.50M	167.50M	0.00	0.00
Gross Profit	462.00K	167.50M	-4.09M	-3.82M
EBITDA	-124.34M	60.88M	-94.46M	-107.21M
Net Income	-120.80M	52.23M	-100.42M	-114.94M
Balance Sheet
Total Assets	303.52M	240.54M	71.50M	149.96M
Cash, Cash Equivalents and Short-Term Investments	264.54M	196.81M	29.16M	99.92M
Total Debt	25.01M	26.63M	49.62M	32.05M
Total Liabilities	41.28M	551.73M	445.35M	432.42M
Stockholders Equity	262.24M	-311.18M	-373.85M	-282.46M
Cash Flow
Free Cash Flow	-106.63M	74.81M	-87.27M	-101.17M
Operating Cash Flow	-105.22M	75.95M	-86.83M	-99.20M
Investing Cash Flow	-1.40M	-1.15M	-441.00K	-3.17M
Financing Cash Flow	196.10M	92.85M	16.39M	1.73M

Maze Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$659.52M	―		―	―	―
GERN	54 Neutral	$880.46M	―	-31.09%	―	11877.28%	63.14%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
CRMD	47 Neutral	$955.51M	16.61	38.35%	―	14970.29%	―
KALV	45 Neutral	$759.30M	―	-121.50%	―	―	-10.46%
NUVB	45 Neutral	$1.17B	―	-64.40%	―	900.35%	70.25%
ANAB	44 Neutral	$590.46M	―	-343.83%	―	304.17%	29.37%